| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e4facac0d1b4ada1864360f710d774f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12M35-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0697 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078 |
| filingDate |
2020-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_376d43e49d567eaf1ba4627ceab091c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_409cd923d7aeeda6b93da437013d28df |
| publicationDate |
2021-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021092555-A2 |
| titleOfInvention |
Methods of screening to determine effective dosing of cancer therapeutics |
| abstract |
In certain example embodiments, the invention contemplates a method of screening therapeutic agents for treating cancer comprising co-culturing immune cells and tumor cells isolated from a subject under conditions that allow the immune cells and the tumor cells to form a cancer spheroid. The cancer spheroid may then be exposed to at least one therapeutic agent, and the responsiveness of the tumor cells in the spheroid to the therapeutic agent may be measured. |
| priorityDate |
2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |